STAT
@statnews
Reporting from the frontiers of health & medicine.
Sign up for any of our newsletters here:
4.7K Following 165.1K Followers
The pregnancy hormone relaxin has long been studied as a potential avenue for a cardiovascular treatment because it can cause blood vessels to widen and relax.
AstraZeneca now has a relaxin agonist that could prove to be effective medicine:
Show more
At the European Society of Cardiology Congress this weekend:
• Novartis drug successfully lowered signs of inflammation in mid-stage study
• AstraZeneca shared details on the surprise failure of its “silencer” drug
Read more takeaways here:
Show more
The latest study on CTE in football players “quantifies but does not reveal a problem,” writes Emily Harrison, a historian who studies brain injury in football.
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.
Researchers believe radiopharmaceuticals have great promise as cancer treatments. But are they using them too timidly?
"We quit the CDC last year. The problems we protested remain. Here’s how Congress can protect the health of our country."
A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study.
Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.
Vaccines take center stage at federal autism advisory committee. Members’ comments linking autism to vaccines overshadowed a proposal to boost autism research funding.
Pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter
“We are concerned the [Lindsay] Clancy case could make psychiatrists more reluctant to treat mothers with mental illness,” write reproductive and forensic psychiatrists.
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
RFK Jr.'s vaccine questions in Samoa, former Stanford president rebuts fraud allegations, and more health news from Morning Rounds
Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news
At a federal autism advisory committee meeting yesterday, committee members explicitly named vaccines as a cause of autism — despite years of scientific evidence debunking any link between the two.
Learn more.
Show more
AstraZeneca and Ionis Pharmaceuticals detailed the surprise failure of their silencer in an ATTR-CM trial.
Investigators think the high proportion of patients already on a stabilizer drug at the start of the trial caused the miss. More details here:
Show more
In today's pharma news:
• The FDA approves a Roivant drug to treat rare autoimmune disease
• AstraZeneca details the surprise failure of a heart disease clinical trial
• Florida AG files antitrust lawsuit against two major PBMS
Read more:
Show more
